
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
B1
Departments of Cancer Biology [B. M. M., C. P. N. D., C. E. B., P. S., C. T., D. J. M., M. B-E.] and Urology [B. M. M., C. P. N. D., C. E. B., P. S.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, and Abgenix, Inc. [X. D. Y., J. M. G.], Fremont, California 94555
Purpose: We previously demonstrated that overexpression of interleukin 8 (IL-8) in human transitional cell carcinoma (TCC) resulted in increased tumorigenicity and metastasis. This increase in tumor growth and metastasis can be attributed to the up-regulation in the expression and activity of the metalloproteinases MMP-2 and MMP-9.
Experimental Design: To investigate whether targeting IL-8 with a fully human anti-IL-8 antibody (ABX-IL8) could be a potential therapeutic strategy for controlling TCC growth, we studied its effects on TCC growth in vitro and in an in vivo mouse model. Human TCC cell lines 253J B-V and UM UC3 (high IL-8 producers), 253J (low IL-8), and 253J transfected with the IL-8 gene (high producer) were used.
Results: ABX-IL8 had no effect on TCC cell proliferation in vitro. However, in the orthotopic nude mouse model, after 4 weeks of treatment (100 µg/week, i.p.), a significant decrease in tumor growth of both cell lines was observed. IL-8 blockade by ABX-IL8 significantly inhibited the expression, activity, and transcription of MMP-2 and MMP-9, resulting in decreased invasion through reconstituted basement membrane in vitro. The down-regulation of MMP-2 and MMP-9 in these cells could be explained by the modulation of nuclear factor-
B expression and transcriptional activity by ABX-IL8.
Conclusions: Our data point to the potential use of ABX-IL8 as a modality to treat bladder cancer and other solid tumors, either alone or in combination with conventional chemotherapy or other antitumor agents.
This article has been cited by other articles:
![]() |
W. M. Merritt, Y. G. Lin, W. A. Spannuth, M. S. Fletcher, A. A. Kamat, L. Y. Han, C. N. Landen, N. Jennings, K. De Geest, R. R. Langley, et al. Effect of Interleukin-8 Gene Silencing With Liposome-Encapsulated Small Interfering RNA on Ovarian Cancer Cell Growth J Natl Cancer Inst, March 5, 2008; 100(5): 359 - 372. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. MacManus, J. Pettigrew, A. Seaton, C. Wilson, P. J. Maxwell, S. Berlingeri, C. Purcell, M. McGurk, P. G. Johnston, and D. J.J. Waugh Interleukin-8 Signaling Promotes Translational Regulation of Cyclin D in Androgen-Independent Prostate Cancer Cells Mol. Cancer Res., July 1, 2007; 5(7): 737 - 748. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Papageorgiou, A. Kamat, W. F. Benedict, C. Dinney, and D. J. McConkey Combination therapy with IFN-{alpha} plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells Mol. Cancer Ther., December 1, 2006; 5(12): 3032 - 3041. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Myers-Irvin, T.-S. Van Le, and R. H. Getzenberg Mechanistic Analysis of the Role of BLCA-4 in Bladder Cancer Pathobiology Cancer Res., August 15, 2005; 65(16): 7145 - 7150. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Di Stefano, A. Capelli, and C. F. Donner Role of Interleukin-8 in the Pathogenesis and Treatment of COPD Chest, September 1, 2004; 126(3): 676 - 678. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |